Prospection works with leading Japanese health data provider Medical Data Vision to improve access to treatment for patients

SYDNEY, September 5, 2022 / PRNewswire / – A pioneer in health analytics, Prospection announced a unique global data access agreement with leading Japanese medical data company Medical Data Vision Co., Ltd. (MDV) to accelerate health analytics to global level.

The agreement, which covers the world’s second largest pharmaceutical market, will provide global pharmaceutical companies and researchers with access to comprehensive, longitudinal data covering more than 40 million people across Japan in more than 470 hospitals.

By combining predictive analytics and machine learning with real-world health data, Prospection’s agreement with MDV will provide pharmaceutical companies around the world with unique access to diagnostic and drug data from patients in hospitals around the world. Japanunlocking the potential to evaluate an unlimited number of treatment programs in the region.

The agreement also allows access to patient history and data at the prefecture level, enabling analysis of disease progression, disease outcomes, and disease course mapping to provide evidence on areas where development can address unmet needs. If further distilled, this creates the opportunity to evaluate patient data regionally to find geographic areas where patients or health centers require additional support for specific diseases and conditions.

Prospect access a of Japan more comprehensive medical datasets is a significant milestone for the company. Prospection currently provides real-time access to longitudinal patient data in 15 regions globally, including Australia, New Zeland, Japan, South Korea, Taiwan, United States of America and the United Kingdom. The company’s latest announcement with Medical Data Vision will build on this work, giving Prospection access to one of the of Japan largest healthcare databases.

Global health benefits

According to academic research, * only 60% of health care is in line with evidence-based guidelines, while the remaining 40% is classified as wasteful, of low value, or in some cases harmful. By analyzing the longitudinal history of hundreds of millions of patients, the Prospection database can help the healthcare industry evaluate the use, value and results of treatments to find that 40% and identify how it can be optimized.

By enabling pharmaceutical companies and healthcare researchers around the world to better understand the full cycle of health conditions and disease pathways, this data will enable global life science companies to:

1. Collect patient and market information

Through the analysis of specific health conditions and patient journeys, pharmaceutical companies can determine where, when and how to invest their resources and how to position their brand within the Japanese pharmaceutical market, while foreseeing the supply chain. and developing models for market access.

2. Find patients and develop tactical plans

Life science companies can use the data to identify where patients with the highest disease burden are geographically treated for their treatment offerings. Companies can then deploy their regional field teams with the right messages to support physicians in helping these patients in need of care.

3. Publish data

Access to one of Japan’s most comprehensive medical datasets also creates the opportunity to add health conditions to the body of clinical evidence to help better understand specific diseases.

4. Get decision support

Provide healthcare professionals with trigger events to assist with targeted education when it is needed most by supporting the physician at the point of care with the patient.

Kaoru SatoCountry Manager, Prospecting, JapanShe said:

“We are pleased to announce our latest agreement with Medical Data Vision. This partnership demonstrates a shared commitment to improving patient outcomes and marks a significant milestone in Prospection’s mission to deliver real community benefits to patients around the world.

“As one of the largest pharmaceutical markets in the world, Japan has incredibly rich datasets. Working with Medical Data Vision gives us the opportunity to access a dataset of approximately 40 million patients, creating a unique opportunity to use advanced analytical tools to accelerate precision medicine to enable the right patient to receive the right treatment. at the right time in his journey.

“The results of this partnership will play a key role in understanding the full cycle of patient health conditions and disease pathways in areas such as immuno-oncology, immune disorders, cardiovascular and metabolic conditions, enabling researchers and pharmaceutical companies around the world to better understand the different characteristics of patients, treatments and respective outcomes “.

Eric ChungCEO and co-founder, Prospection said:

“We are very excited to partner with MDV on our latest data access agreement. The combination of MDV’s broad and comprehensive dataset with Prospection’s global reach and extensive experience working with datasets around the world beyond. will allow MNC pharmaceutical companies to work with patient data from Japan, but it will also open up a broader understanding of different health conditions around the world. This agreement brings us one step closer to improving precision medicine to find 40% of patients who can be optimized. “


* BMC Medicine: The three numbers you need to know about healthcare: the 60-30-10 Challenge

Speaking of prospecting

Prospecting is a pioneer in health data analytics technology. Our mission is to advance precision medicine through real-world testing, with the goal of getting the right patient to the right treatment at the right time. By applying advanced ML algorithms to real-world data, we uncover the healthcare journey and treatment insights by analyzing longitudinal data for hundreds of millions of patients to see how drug treatments are used after clinical trials. Provide real-world practice trials that enable better patient outcomes, around the world.

Prospecting is led by accredited experts and innovative leaders in their respective fields. Globally, we work with over 15 large health data sets (complaints, EMR, registry and commercial), applying our expertise to examine health models. Working with government and researchers down to our core client base in the pharmaceutical / biopharmaceutical industry, we have provided insights into over 90 therapeutic indications. Including rare and complex diseases such as oncology, immuno-oncology, virology, metabolic conditions, respiratory and cardiovascular diseases. Prospection is supported by investors including Ellerston, Horizons Ventures and Main Sequence and commercially by CRO Novotech.

Follow us on:

LinkedIn company: prospecting-au

Twitter Handle: @_Prospection

Facebook ProspectionGlobal Company:

About Medical Data Vision (MDV)

MDV is an accumulation of anonymously processed data with secondary use authorizations from medical institutions. The actual number of patients in the “hospital data” centered on the acute phase is 40.42 million (counted at the end of July 2022). In addition, by retaining health insurance association data, recovery period and chronic period data have been improved and, in addition to hospital / clinic information, it has become possible to track information about transfer destinations. The “health insurance data” was 7.84 million people (same).



View original content to download multimedia content: -access-for-patients-301617901.html

SOURCE Prospecting

Leave a Comment

Your email address will not be published.